Table 4. Geometric mean of anti-HBsAg (GMT), percentage of subjects with increasing antibody titer ≥4 times and percentage of subjects with the transition of seronegative to seropositive.
| Description | 0118S (n=131) | 0218S (n=133) | 0318S (n=127) | Control (n=130) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | ||
| GMT mIU/mL | |||||||||
| Mean | 1.376 | 4,088.826 | 2.118 | 8,214.546 | 2.373 | 5,154.18 | 2.119 | 1,520.126 | |
| (95% CI) | (0.822–2.301) | (3,107.420–5,380.220) | (6,032.537–11,186.649) | (1,105.350–2,090.740) | (1.398–4.026) | (3,752.321–7,079.458) | (1.232–3.645) | (1,105.350–2,090.740) | |
| Anti-HbsAg ≥10 mIU/mL (%SP) | 32 (24.43) | 131 (100.00) | 34 (25.564) | 132 (99.25) | 35 (27.56) | 127 (100.00) | 37 (28.46) | 129 (99.23) | |
| Subjects with increasing antibody titer ≥4 times (%SC) | - | 131 (100.00) | - | 133 (100.00) | - | 127 (100.00) | - | 127 (97.69) | |
| Subjects with transition of seronegative to seropositive (%SC) | - | 99 (100.00) | - | 98 (98.99) | - | 92 (100.00) | - | 92 (98.925) | |
Values are presented as mean (95% CI) or number of available observations (%), unless otherwise stated.
HBsAg, hepatitis B surface antigen; GMT, geometric mean titer; CI, confidence interval; %SP, seroprotection rate; %SC, seroconversion rate.